Focused Shock Wave Therapy Outcomes in Peyronie's Disease and Erectile Dysfunction
Launched by MAYO CLINIC · Dec 2, 2022
Trial Information
Current as of January 16, 2025
Withdrawn
Keywords
ClinConnect Summary
No description provided
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Peyronie's Disease (PD) at any stage
- • The presence of penile plaque or pain at erection or curvature
- • PD therapy with or without simultaneous intralesional Xiaflex injection.
- Exclusion Criteria:
- • Prior penile surgery or LiSWT.
- • Erective Dysfunction (ED) not responding to phosphodiesterase-type five inhibitors or intracavernosal injections.
- • Unwillingness or inability to provide informed consent.
- • Having active or life-threatening coagulopathies ore using anti-coagulation /anti-platelet medications
Trial Officials
Tobias Kohler, MD, MPH
Principal Investigator
Mayo Clinic
About Mayo Clinic
Mayo Clinic is a renowned nonprofit medical practice and research institution dedicated to providing comprehensive healthcare and advancing medical knowledge through innovative research and education. With a commitment to patient-centered care, Mayo Clinic conducts numerous clinical trials aimed at exploring new therapies and improving treatment outcomes across various disciplines. Leveraging a multidisciplinary approach, the institution collaborates with leading experts and cutting-edge technology to ensure rigorous scientific standards and ethical practices in all its research endeavors. Through its trials, Mayo Clinic seeks to translate breakthroughs in science into tangible benefits for patients, fostering advancements in medicine that enhance health and quality of life.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Rochester, Minnesota, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials